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OBJECTIVES The Study to COmpare REstenosis Rate between QueST and QuaDDS-QP2 (SCORE)
trial was a multicenter, randomized, open-label trial comparing the safety and performance of
13- and 17-mm QuaDDS stents (n  126) (Quanam Medical Corp., Santa Clara,
California/Boston Scientific Corp., Natick, Massachusetts) versus uncoated control stents (n
 140) in focal, de novo coronary lesions.
BACKGROUND The pioneering drug-delivery QuaDDS stent used four to six acrylate polymer sleeves, each
loaded with 800 g of the paclitaxel derivative 7-hexanoyltaxol.
METHODS Clinical end points were assessed at 1, 6, and 12 months post procedure. Quantitative
coronary angiography and intravascular ultrasound were performed post procedure and at
six-month follow-up.
RESULTS In the QuaDDS group, early stent thrombosis and myocardial infarction (MI) rates were
significantly higher, leading to premature cessation of enrollment. For the QuaDDS group,
the stent thrombosis rate increased from 3.2% to 10.3% between 1 and 12 months, associated
with increased non–Q-wave MI and death rates. The angiographic restenosis rate at six
months was reduced from 32.7% (control) to 7.4% (p  0.0001). However, the primary end
point was not met with six-month target vessel revascularization (TVR) rate as well as the
composite major adverse cardiac event rates (cardiac death, MI, and TVR) comparable
between groups.
CONCLUSIONS Despite angiographic indications of potential anti-restenotic benefit, increased rates of stent
thrombosis, MI, and cardiac death associated with the QuaDDS stent show an unacceptable
safety profile. (J Am Coll Cardiol 2004;44:1368–72) © 2004 by the American College of
Cardiology Foundatione
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Qhe use of bare metal coronary stents after balloon angio-
lasty has decreased, but not eliminated, restenosis and the
ubsequent need for repeat revascularization procedures (1).
or this reason, drug-eluting stents that provide antiprolif-
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cientific Corporation, Natick, Massachusetts. Dr. Russell is an employee and
tockholder of Boston Scientific Corp. Dr. Guagliumi consults for Boston Scientific
orp. The Cardiovascular Research Foundation (Dr. Lansky) receives educational
rants from Boston Scientific Corp. The SCORE trial was initiated and sponsored by
uanam Medical Corp. (Santa Clara, California) in February 2000. Boston Scientific
orp. acquired Quanam in February 2001 and assumed responsibility for new trial
anagement.
Manuscript received March 8, 2004; revised manuscript received April 8, 2004,sccepted June 14, 2004.rative drugs to the stented vessel wall have been designed
nd studied for reducing in-stent restenosis.
The pioneering QuaDDS stent (Quanam Medical Corp.,
anta Clara, California/Boston Scientific Corp., Natick,
assachusetts) was designed to control neointimal prolif-
ration through prolonged high-dose delivery of the pacli-
axel derivative 7-hexanoyltaxol (QP2) via acrylate polymer
embranes mounted on a novel stent design (QueST).This
echnology differs markedly from subsequent paclitaxel-
luting stents that use drug or drug-polymer coatings to
eliver low-dose paclitaxel to inhibit restenosis (2–5).
We report final one-year outcomes from the Study
o COmpare REstenosis Rate between QueST and
uaDDS-QP2 (SCORE) trial.
ETHODS
tudy design. The open-label, randomized, multicenter
CORE trial compared safety and performance of the
uaDDS stent versus the QueST, or other, bare metaltents in focal, de novo coronary lesions. Ethics Review
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October 6, 2004:1368–72 7-Hexanoyltaxol-Eluting Sleeve Stentommittees of participating institutions approved the pro-
ocol, and patients provided written informed consent
efore enrollment.
Enrollment, planned for 400 patients in 19 international
ites, began in February 2000. In April 2001, enrollment
as terminated prematurely (266 patients, 15 sites, 4 coun-
ries) because of unexpectedly high rates of adverse cardiac
vents (stent thrombosis cardiac death, and myocardial
nfarction [MI]).
atient selection. Eligible patients (51 to 79 years of age)
ad documented de novo lesions in native coronary arteries,
bjective evidence of ischemia (stable/unstable angina, pos-
tive functional study), and clinical, hemodynamic, and
ngiographic indications for percutaneous transluminal cor-
nary angioplasty. Key angiographic inclusion criteria were
esion length suitable for a single 13- or 17-mm stent with
tenosis50% and location in a native coronary vessel3.0
m and 3.5 mm in diameter.
Key exclusion criteria included excessive tortuosity, in-
olvement of side branch 2.0 mm in diameter, moderate
r severe calcification of the target lesion or adjacent vessel,
cute MI 1 week before the procedure, stroke or transient
schemic attack 6 months before the procedure, and
llergy or contraindication to aspirin, clopidogrel, ticlopi-
ine, heparin, or stainless steel.
nd points. Clinical end points included stent thrombosis
ate and major adverse cardiac event (MACE), defined as
ardiac death, Q-wave and non–Q-wave MI, and revascular-
zation of the target lesion (coronary artery bypass graft or
ercutaneous coronary intervention). An independent Clinical
vents Committee adjudicated MACE. The primary end
oint six months post procedure was the target vessel revascu-
arization (TVR) rate; secondary end points were MACE,
uantitative coronary angiography (QCA), and intravascular
ltrasound (IVUS) assessments of restenosis. Successful reduc-
ion was predefined as a restenosis rate 20%.
evice. Control devices included commercially available
ncoated stents and balloon-expandable (13- or 17-mm
ong; 3.0- or 3.5-mm diameter) QueST stents made of
16L surgical-grade stainless steel in a slotted tube design
Abbreviations and Acronyms
IVUS  intravascular ultrasound
MACE  major adverse cardiac event
MI  myocardial infarction
QCA  quantitative coronary angiography
TLR  target lesion revascularization
TVR  target vessel revascularizationFigure 1. Photograph of the QuaDDSnd mounted on an over-the-wire balloon catheter delivery
ystem. The test stent (QuaDDS) was the QueST stent
ounted with polymer sleeves with 800 g 7-hexanoyltaxol
ach (Fig. 1). The 13-mm stent contained 4 sleeves
3.2 mg); the 17-mm had 5 sleeves (4.0 mg).
rocedures. Patients, randomized to QuaDDS or control
tents, received a loading dose of ticlopidine (500 mg) or
lopidogrel (150 to 300 mg) 24 h before the procedure and
eparin to maintain an active clotting time of 250 s. Post
rocedure, the protocol mandated aspirin (100 mg daily)
ndefinitely. Ticlopidine (250 mg twice a day) or clopidogrel
75 mg every day) treatment, initially mandated for either one
onth (control) or six months (QuaDDS), was amended to
ne year for the QuaDDS stent.
ollow-up. Clinical follow-up was conducted at 1, 6, and
2 months post procedure. Coronary angiography was
erformed before and immediately after the index procedure
nd at six-month follow-up or when a patient presented
ith cardiac symptoms. An independent core laboratory
Cardiovascular Research Foundation, New York, New
ork) following established methodology performed QCA
nalyses. In-stent restenosis assessments included percent
iameter stenosis, minimum lumen diameter, reference
essel diameter, acute gain, late loss, and restenosis rate
percent with 50% diameter stenosis). Intravascular ultra-
ound assessment was performed on 122 patients (66
uaDDS; 56 control) immediately post procedure and
gain at six months (6).
tatistical analysis. Final data management and statistical
nalyses were performed by PAREXCEL International Ltd.
Waltham, Massachusetts). The primary study hypothesis was
hat the QuaDDS stent would reduce in-stent restenosis rates
ompared with bare metal stents (7,8). Statistical analyses,
erformed using SAS version 6.12 (SAS Institute, Cary, North
arolina), were based upon actual stent received to assess the
afety performance of the stent. Continuous variables are
ummarized as mean  SD and compared between treatment
roups using a two-sample t test. Categorical variables are
xpressed as percentages and compared using two-sided Fish-
r’s exact test. Survival analyses for freedom from MACE and
arget lesion revascularization (TLR) were performed using the
aplan-Meier product-limit method and compared using the
og-rank test. A p value 0.05 was considered statistically
ignificant.
ESULTS
he SCORE trial was terminated prematurely (266 pa-
ients) in April 2001 owing to a high rate of adverse cardiacstent with five polymer sleeves.
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7-Hexanoyltaxol-Eluting Sleeve Stent October 6, 2004:1368–72vents as recommended by the Clinical Oversight Commit-
ee. Long-term results were collected for 91% (244 of 266)
nd 76% (201 of 266) of patients at six-month clinical and
ngiographic follow-up, respectively, and for 88% (235 of
66) at 12-month clinical follow-up. The Clinical Over-
ight Committee also recommended that the SCORE trial
atients be maintained on clopidogrel and followed in a
ong-term registry.
aseline and procedural characteristics. Groups showed
o significant differences with respect to baseline demo-
raphics and clinical characteristics (Table 1). Mean lesion
engths (QCA) were comparable (11.7  4.4 mm
QuaDDS]; 12.0  4.4 mm). Stent placement with post-
rocedure percent diameter stenosis 20% was comparable
99.7% [QuaDDS]; 99.8%).
linical outcomes. In the QuaDDS group, stent throm-
osis rates were higher at 1, 6, and 12 months and were
ssociated with increased rates of cardiac death and MI
Table 2). The risk for cardiac death or MI in QuaDDS
atients who had a stent thrombosis was 84.6%, signifi-
antly higher than for those who did not (p  0.001).
mong QuaDDS patients with a stent thrombosis, 23.1%
3 of 13) had associated death, 76.9% (10 of 13) had
ssociated MI, and 15.4% (2 of 13) had associated cardiac
eath and MI.
One-month overall MACE rates were higher in the
uaDDS group, attributable in part to an increase in MI,
ost likely related to polymer sleeve side branch occlusion.
The six-month primary end point was not met. Group
able 1. Baseline Demographics and Clinical Characteristics
Characteristic*
QuaDDS
(n  126)
Control
(n  140†)
ender, male (%) 81 78
ge, yrs (min, max)‡ 61 (33, 79) 63 (34, 80)
iabetes (%) 20 21
ypertension (%) 68 64
revious myocardial infarction (%) 39 41
ypercholesterolemia (%) 72 78
urrent smoking (%) 16 18
No statistically significant differences between groups (p  0.05). †QueST: 111;
ommercial uncoated: 29. ‡In accordance with the protocol, eligible patients were
etween 50 and 80 years old but five patients under 50 were enrolled.
able 2. 1-, 6-, and 12-Month Cumulative MACE and Stent T
Event
1 Month
QuaDDS
(n  126)
Control*
(n  140) p†
ACE 16 (12.7%) 4 (2.9%) 0.004
Cardiac death 2 (1.6%) 0 (0.0%) 0.223
MI 15 (11.9%) 3 (2.1%) 0.002
Q-wave MI 1 (0.8%) 0 (0.0%) 0.474
Non–Q-wave MI 13 (10.3%) 3 (2.1%) 0.008
Target vessel revascularization 3 (2.4%) 1 (0.7%) 0.348
Target lesion revascularization 3 (2.4%) 1 (0.7%) 0.348
tent thrombosis 4 (3.2%) 0 (0.0%) 0.049
Included two patients randomized to the QuaDDS stent who erroneously received
MACE  major adverse cardiac events; MI  myocardial infarction.ACE rates were comparable as a result of similar TVR
ates (Table 2). However, the QuaDDS group showed
igher rates of overall MI and non–Q-wave MI.
Twelve-month MACE rates were similar but the
uaDDS group showed higher rates of MI and cardiac
eath. The groups had similar survival curves for freedom
rom MACE and freedom from TLR (Fig. 2).
CA and IVUS. At six-month follow-up, the restenosis
ate was reduced from 32.7% (control) to 7.4% (QuaDDS
p  0.0001]) (Table 3). The QuaDDS group minimum
umen diameter was larger; percent diameter stenosis and
ate loss were lower (Table 3).
The IVUS outcomes showing a 68% reduction in neoin-
imal growth and a 28% increase in minimum lumen area in
he QuaDDS group versus control patients were published
reviously (6).
ISCUSSION
he pioneering QuaDDS stent’s unacceptable safety profile
nd failure to impact revascularization have halted further
evelopment of this high-dose, acrylate polymer sleeve
elivery system. The safety outcomes from this mode of
aclitaxel delivery stand in stark contrast to acceptable
esults obtained with other paclitaxel-eluting coated stents
2–5,9). Factors that may have contributed to the increased
tent thrombosis, non–Q-wave MIs, and death are outlined
n the following discussion.
rug. Drug doses loaded on the QuaDDS stent were
10-fold above the TAXUS paclitaxel-eluting stents (e.g.,
7-mm QuaDDS stent, 4,000 g; 16-mm TAXUS stent,
08 g) (2). Second, release was protracted for QuaDDS,
ith most (80%) 7-hexanoyltaxol release occurring within
0 days and continuing to six months (Quanam/Boston
cientific preclinical data on file). This contrasts with burst
elease of the paclitaxel within the first 48 h for the other
aclitaxel-eluting stents. Hence, higher drug doses for a
onger time may have delayed healing and prevented surface
assivation, contributing to the QuaDDS stent’s higher
tent thrombosis rate.
olymer. Long-term (90- and 180-day) porcine studies
onducted subsequent to SCORE enrollment demonstrated
bosis
6 Months 12 Months
DDS
126)
Control*
(n  140) p†
QuaDDS
(n  126)
Control*
(n  140) p†
0.6%) 20 (14.3%) 0.196 37 (29.4%) 35 (25.0%) 0.490
.4%) 0 (0.0%) 0.105 5 (4.0%) 0 (0.0%) 0.023
5.9%) 3 (2.1%)  0.001 24 (19.0%) 3 (2.1%)  0.001
.4%) 0 (0.0%) 0.105 6 (4.8%) 0 (0.0%) 0.011
1.9%) 3 (2.1%) 0.002 16 (12.7%) 3 (2.1%) 0.001
1.9%) 18 (12.9%) 0.854 25 (19.8%) 33 (23.6%) 0.552
.9%) 14 (10.0%) 0.670 18 (14.3%) 26 (18.6%) 0.410
.1%) 1 (0.7%) 0.007 13 (10.3%) 1 (0.7%)  0.001
rol stent. †Two-sided Fisher’s exact tests; p  0.05  statistically significant.hrom
Qua
(n 
26 (2
3 (2
20 (1
3 (2
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October 6, 2004:1368–72 7-Hexanoyltaxol-Eluting Sleeve Stentn intense inflammatory reaction with frequent granulomas
nd fibrosis with severe narrowing and occlusion in vessels
tented with the QuaDDS stent or polymer-only sleeves
Boston Scientific data on file), indicative of vascular in-
ompatibility of the polymer sleeves alone and with
-hexanoyltaxol. These proinflammatory findings in the
orcine model with the acrylate polymer may suggest
dditional mechanisms contributing to the poor QuaDDS
afety profile in humans.
leeves. Multiple, relatively thick sleeves could potentially
Figure 2. Freedom from (A) major adverse cardiac event (MAlock side branches, leading to higher rates of periproce- pural non–Q-wave MI. In contrast, paclitaxel-eluting stents
sing strut-conforming drug coatings have established safe
linical trial profiles (2,3,5,9).
ONCLUSIONS
espite the limitations of open-label design, the SCORE
rial outcomes demonstrate that for the QuaDDS stent, the
otential anti-restenotic benefit seen with reduced binary
estenosis rates is outweighed by an unacceptable safety
and (B) target lesion revascularization (TLR) post-procedure.CE)rofile. Incomplete healing suggested by ongoing stent
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7-Hexanoyltaxol-Eluting Sleeve Stent October 6, 2004:1368–72hrombosis and associated MACE argue that the goal for
aclitaxel delivery is transient and low-level paclitaxel re-
ease as opposed to the QuaDDS design with protracted and
igh-dose release of 7-hexanoyltaxol.
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PPENDIX
n independent Clinical Events Committee whose mem-
ers were Stephen G. Ellis, MD, Patrick L. Whitlow, MD,
nd E. Murat Tuzcu, MD, of the Cleveland Clinic Foun-
ation, adjudicated MACE.
The Clinical Oversight Committee, consisting of Mary
. Russell, MD, David O. Williams, MD, and Simon
tertzer, MD, recommended that the SCORE trial be
rematurely terminated owing to a high rate of adverse
Angiographic Outcomes in the SCORE
* (n) Control* (n) p†
(116) 3.00 0.48 (132) 0.12
(113) 11.98 4.35 (130) 0.60
(116) 0.92 0.46 (133) 0.99
7 (116) 69.86 12.95 (132) 0.46
(114) 3.06 0.44 (132) 0.11
(116) 2.91 0.46 (133) 0.01
5 (114) 4.43 10.50 (132) 0.16
(94) 1.79 0.76 (107)  0.0001
(94) 39.5 23.9 (107)  0.0001
4) 32.7% (107)  0.0001
(94) 1.08 0.79 (107)  0.0001
data: two-sided Fisher’s exact test; p  0.05  statistically
ized groups. §50% in-stent diameter stenosis, excluding
t and QuaDDS-QP2.nth
DDS
0.43
4.38
0.38
12.1
0.38
0.37
10.2
0.54
18.1
4% (9
0.58
inary
randomardiac events.
